Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEPI: Protracted Etoposide in High Risk Neuroblastoma
NCT00578864Phase 2Completed
- Sponsor
- Baylor College of Medicine
- Start
- Mar 2007
- Primary completion
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of etoposide in neuroblastoma (2 arms), sponsored by Baylor College of Medicine. Primary endpoints: Response Rate Associated With Two Cycles of Cisplatin With Protracted Oral Etoposide at 2 months and Rate of Toxicities Associated With Cisplatin With Protracted Oral Etoposide at 2 months. Started Mar 2007; status: completed.
02
Drugs
etoposide
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT00578864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00578864.